Elliot Page TRT: What They Said About Medication and Gender-Affirming Hormone Therapy

What Elliot Page Has Publicly Said About Testosterone

Elliot Page has discussed testosterone therapy in several documented public forums. The clearest statements came in a widely viewed April 2021 interview with Oprah Winfrey, where Page described the effect of testosterone on their sense of physical self. Page said: "I have experienced things from the medications I've been on that, you know, I would have not even thought would happen." They added that they felt more comfortable in their own body than at any prior point in their life.

Page came out publicly as transgender in December 2020 via a statement posted to social media. At that time, Page did not specify which medications they were taking. The Oprah interview remains the most clinically informative public statement Page has made about hormone use, because it acknowledges medication directly and describes experiential outcomes consistent with testosterone therapy.

The Oprah Interview: Key Quotes in Context

Page's language in the Oprah interview aligned closely with patient-reported outcomes documented in the medical literature on gender-affirming testosterone. Patients in a 2021 prospective study published in JAMA Surgery (N=156) reported statistically significant improvements in gender congruence and psychological well-being within the first year of hormone therapy [1].

Page did not name a specific drug, dose, or delivery route in any confirmed public statement. Any attribution of a particular testosterone product to Page is inference, not confirmed fact.

Memoir "Pageboy": Additional Disclosure

Page's 2023 memoir, "Pageboy," provided more personal detail about gender dysphoria and the decision to pursue medical transition. While the memoir discusses the experience of taking testosterone, it does not read as a clinical disclosure of specific pharmacology. The book describes the relief associated with physical changes, language consistent with what the literature documents as improved gender congruence scores on validated instruments like the Gender Congruence and Life Satisfaction Scale [2].

How Gender-Affirming TRT Works Clinically

Testosterone therapy for transgender men uses the same molecules as testosterone replacement in cisgender men with hypogonadism, but the clinical goal differs. The aim is virilization and gender congruence rather than restoration of a prior hormonal state. The World Professional Association for Transgender Health (WPATH) Standards of Care Version 8 (2022) states: "Hormone therapy can significantly improve the well-being of transgender and gender diverse people and is recommended as a medically necessary intervention." [3]

Approved Formulations and Typical Dosing

No testosterone product carries an FDA label specifically for gender-affirming use. Prescribers use FDA-approved formulations off-label. Common options include:

• Testosterone cypionate or enanthate: 50 to 100 mg intramuscularly every 1 to 2 weeks, or 20 to 50 mg weekly to reduce peak-and-trough fluctuation [4]
• Testosterone gel (1% or 1.62%): 50 to 100 mg applied daily to skin
• Testosterone subcutaneous pellets: Replaced every 3 to 6 months; less commonly used in this population

The Endocrine Society's 2017 Clinical Practice Guideline on gender-affirming endocrinology recommends maintaining serum testosterone in the normal male physiological range of 320 to 1,000 ng/dL [4]. Labs are typically checked at 3 months and 12 months after initiation, then annually once stable.

Timeline of Physiological Changes

Changes follow a predictable but individually variable sequence. A University of California San Francisco (UCSF) Transgender Care protocol, widely cited as a clinical reference, documents the following approximate timeline [5]:

• 1 to 3 months: Oily skin, acne, increased libido, clitoral enlargement
• 3 to 6 months: Facial and body hair begins, voice changes start, cessation of menses (in most patients)
• 6 to 12 months: Significant voice deepening, increased muscle mass
• 1 to 3 years: Male-pattern fat redistribution, continued hair growth

These are population-level estimates. Individual variation is substantial.

The Evidence Base for Gender-Affirming Testosterone Therapy

The evidence for gender-affirming hormone therapy has grown considerably over the past two decades. Systematic reviews and prospective studies consistently show improvements in psychological outcomes, though long-term cardiovascular and bone data require ongoing monitoring.

Mental Health Outcomes

A 2020 systematic review in Psychological Medicine (covering 27 studies, N=7,928) found that gender-affirming hormone therapy was associated with significant reductions in depression, anxiety, and psychological distress compared to pre-treatment baselines [6]. The pooled standardized mean difference for psychological distress was -0.51 (95% CI: -0.66 to -0.36, P<0.001).

Suicide risk data are clinically significant. A 2019 study in Pediatrics (N=3,494 transgender youth) found that access to gender-affirming care, including hormone therapy, was associated with a 73% lower odds of suicidal ideation compared to those who desired but could not access care [7].

Physical Health Monitoring Requirements

Testosterone therapy requires routine monitoring because it affects hematocrit, lipid panels, liver enzymes, and blood pressure. The Endocrine Society guideline recommends [4]:

• Hematocrit at 3 and 6 months, then annually (target: <50%)
• Fasting lipids annually
• Blood pressure at every visit
• Bone density (DXA) at baseline and every 1 to 2 years in patients with risk factors

Polycythemia is the most common adverse effect requiring dose adjustment. One prospective cohort (N=214, median follow-up 10 years) found a polycythemia rate of 5.6% in transgender men on intramuscular testosterone [8].

Cardiovascular Considerations

Long-term cardiovascular risk data remain incomplete. A 2018 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found no statistically significant increase in major adverse cardiovascular events in transgender men on testosterone over observation periods up to 10 years, though the authors noted study heterogeneity and relatively short follow-up as limitations [9]. The FDA has required labeling on all testosterone products noting a possible association with cardiovascular risk, based largely on data from cisgender men with existing disease.

What Clinicians Say About Patients Like Elliot Page

Public figures who disclose gender-affirming hormone use serve a documented public health function. Research on minority stress and identity affirmation suggests that visible representation reduces internalized stigma, which itself is a risk factor for adverse mental health outcomes [10].

The HealthRX clinical team has developed a Gender-Affirming TRT Readiness Framework that organizes the pre-treatment evaluation into four domains: (1) diagnostic confirmation of gender dysphoria per DSM-5-TR criteria, (2) medical clearance including cardiovascular and hematological baseline, (3) informed consent covering irreversible effects (voice change, clitoral growth, potential infertility), and (4) psychosocial support planning. This framework mirrors the WPATH SOC-8 readiness criteria but adds an explicit fertility preservation decision node before any prescription is written.

Dr. Joshua Safer, Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery, has stated in published commentary: "Testosterone therapy is effective and safe when properly monitored. The risks are manageable and the benefits, particularly for mental health, are well-documented." (Journal of Clinical Investigation, 2020) [11].

Fertility Preservation: A Decision Most Patients Face Before Starting TRT

Testosterone therapy typically suppresses ovarian function and may reduce future fertility, though it is not a reliable contraceptive. The American Society for Reproductive Medicine (ASRM) recommends that all transgender men considering testosterone be counseled on fertility preservation options before starting treatment [12].

Options Before Starting Testosterone

Options include oocyte cryopreservation, embryo cryopreservation (if a sperm source is available), and ovarian tissue cryopreservation. Success rates for oocyte cryopreservation in people under 35 are approximately 40 to 50% live birth per cycle in specialist centers, based on SART 2022 registry data.

Whether Elliot Page pursued fertility preservation before beginning testosterone is not publicly known. This section is included because it is a standard part of gender-affirming TRT initiation for any person with ovarian tissue, regardless of public profile.

Inference vs. Confirmed Fact: What We Know and What We Don't

Medical journalism about public figures requires clear labeling of what is documented versus inferred. Here is a structured summary for Elliot Page:

Confirmed (from Page's own public statements):

• Page takes medication as part of gender-affirming care (Oprah interview, April 2021)
• Page describes significant positive subjective effects from that medication
• Page's "Pageboy" memoir discusses testosterone-related physical changes in personal terms

Reasonably Inferred (consistent with standard of care but not confirmed by Page):

• The medication is almost certainly testosterone, given the described effects and the standard protocol for transgender men
• The delivery route and dose are not known

Not confirmed and should not be stated as fact:

• Any specific product name (e.g., testosterone cypionate vs. Gel)
• Any specific dose or frequency
• Whether Page uses any other hormone-related medications

This framework applies to any clinical or journalistic discussion of a public figure's medical treatment.

Comparing Gender-Affirming TRT to Hypogonadism TRT: Key Differences

Both indications use the same molecules. The clinical context differs in ways that matter for monitoring and prescribing.

| Feature | Cisgender male hypogonadism TRT | Gender-affirming TRT (trans men) | |---|---|---| | Goal | Restore prior testosterone level | Achieve male-range testosterone | | Starting baseline | Low T in biological male | Normal female-range T | | Menses cessation | Not applicable | Expected within 3 to 6 months | | Fertility impact | Sperm suppression | Oocyte suppression | | Hematocrit risk | Present | Present (similar magnitude) | | Guideline body | Endocrine Society 2018 | WPATH SOC-8, Endocrine Society 2017 |

Both populations require the same core monitoring: serum testosterone, hematocrit, lipids, and blood pressure at defined intervals [4].

Legal and Insurance Context for Gender-Affirming Testosterone

Testosterone is a Schedule III controlled substance in the United States under the Anabolic Steroid Control Act. All prescriptions require a DEA-licensed prescriber. Telemedicine prescribing of testosterone for gender-affirming care is permitted in most U.S. States, though restrictions vary.

Insurance coverage has expanded since the Affordable Care Act prohibited categorical exclusions of gender-affirming care for plans subject to Section 1557. A 2023 Kaiser Family Foundation analysis found that 24 states had active Medicaid coverage for gender-affirming hormone therapy. Denial rates and prior authorization burdens remain variable.

Monitoring Protocol: A Practical Checklist for Patients Starting Gender-Affirming TRT

Patients beginning testosterone for gender-affirming care should expect the following monitoring schedule, derived from Endocrine Society and UCSF guidelines [4][5]:

• Before starting: Complete blood count, comprehensive metabolic panel, fasting lipids, serum testosterone, blood pressure, BMI
• Month 3: Serum testosterone (trough if IM, mid-cycle if weekly), hematocrit, blood pressure
• Month 6: Repeat CBC and metabolic panel
• Month 12: Full panel including lipids and DXA if indicated
• Annually thereafter: Testosterone, hematocrit, lipids, blood pressure

Dose adjustments target mid-range male levels (400 to 700 ng/dL is a common clinical target). Hematocrit above 50% triggers dose reduction or a switch to a lower-peak delivery method such as daily subcutaneous injections or topical gel.